1. EGFR Mutations in Lung Adenocarcinomas
Allan R. Li, Dhananjay Chitale, Gregory J. Riely, William Pao, Vincent A. Miller, Maureen F. Zakowski, Valerie Rusch, Mark G. Kris, Marc Ladanyi 
The Journal of Molecular Diagnostics 
Volume 10, Issue 3, Pages (May 2008)
DOI: /jmoldx
Copyright © 2008 American Society for Investigative Pathology and Association for Molecular Pathology Terms and Conditions

2. Figure 1
A and B: Adenocarcinoma with 15-bp EGFR exon 19 deletion. The mutant peak is to the left of the 207-bp normal peak. C and D: BAC with EGFR exon 21 L858R mutation. The 87-bp product of this PCR-RFLP assay represents the mutant allele (see Materials and Methods for details).
The Journal of Molecular Diagnostics  , DOI: ( /jmoldx )
Copyright © 2008 American Society for Investigative Pathology and Association for Molecular Pathology Terms and Conditions

3. Figure 2
A and B: Cases with EGFR exon 19 deletions (of different sizes) showing three- and fivefold copy number gains of the mutant allele relative to the 207-bp normal allele.
The Journal of Molecular Diagnostics  , DOI: ( /jmoldx )
Copyright © 2008 American Society for Investigative Pathology and Association for Molecular Pathology Terms and Conditions

4. Figure 3
A: Chromogenic in situ hybridization showing no amplification, low-level amplification, and high-level amplification of the EGFR gene in three different lung adenocarcinomas. B: Lung adenocarcinomas with different levels of EGFR IHC staining: 0; 1+; 2+; 3+. Examples of both EGFR mutant and EGFR non-mutant cases are shown. C: Venn diagram showing relationships between EGFR mutations, EGFR amplification, and EGFR overexpression in a set of 60 lung tumors.
The Journal of Molecular Diagnostics  , DOI: ( /jmoldx )
Copyright © 2008 American Society for Investigative Pathology and Association for Molecular Pathology Terms and Conditions